Shimohigashi Y, Hatano R, Fujita T, Nakashima R, Nose T, Sujaku T, Saigo A, Shinjo K, Nagahisa A
Laboratory of Biochemistry, Department of Chemistry, Faculty of Science, Kyushu University, Fukuoka 812-81, Japan.
J Biol Chem. 1996 Sep 27;271(39):23642-5. doi: 10.1074/jbc.271.39.23642.
Nociceptin or orphanin FQ is a novel neuropeptide that activates an opioid-like G protein-coupled receptor ORL1. This heptadecapeptide FGGFTGARKSARKLANQ resembles kappa-opioid peptide dynorphin A but exhibits an opposite effect to make animals hyperreactive to nociceptive stimulations (Meunier, J.-C., Mollereau, C., Toll, L., Suaudeau, C., Moisand, C., Alvinerie, P., Butour, J.-L., Guillemot, J.-C., Ferrara, P., Monsarrat, B., Mazarguil, H., Vassart, G., Parmentier, M., and Costentin, J. (1995) Nature 377, 532-535; Reinscheid, R. K., Nothacker, H.-P., Bourson, A., Ardati, A., Henningsen, R. A., Bunzow, J. R., Grandy, D. K., Langen, H., Monsma, F. J., Jr., and Civelli, O. (1995) Science 270, 792-794). In the present study, it was found that guinea pig brain contains receptors to which nociceptin binds much more strongly than to ORL1 receptors expressed in human 293 cells. Although the Tyr1 --> Phe substitution for dynorphin A eliminates almost completely an ability to bind to opioid receptors, the Phe1 --> Tyr substitution in nociceptin was found to retain almost fully both receptor binding affinity and in vivo hyperalgesic activity in tail-flick assay. Nociceptin was extremely weak to bind to opioid receptors, while Tyr1-nociceptin exhibited 10-40 times increased affinity, especially for mu receptors, due to its N-terminal sequential identity to opioid peptides. Shortened analogs of dynorphin A are known to retain receptor binding ability and analgesic activity, whereas the removal of C-terminal hexa- or decapeptide from nociceptin totally abolished the affinity for the ORL1 receptor. These results indicated that the mode of interaction between nociceptin and ORL1 receptor is quite different from that between dynorphin and opioid receptor and that the C-terminal portion of nociceptin is crucial for receptor recognition.
痛敏肽或孤啡肽FQ是一种新型神经肽,它可激活一种类阿片G蛋白偶联受体ORL1。这种十七肽FGGFTGARKSARKLANQ与κ-阿片肽强啡肽A相似,但却表现出相反的效应,使动物对伤害性刺激反应过度(默尼耶,J.-C.,莫勒罗,C.,托尔,L.,叙奥多,C.,穆瓦桑,C.,阿尔维内里,P.,比图尔,J.-L.,吉耶莫,J.-C.,费拉拉,P.,蒙萨拉,B.,马扎吉尔,H.,瓦萨尔,G.,帕尔芒捷,M.,和科斯坦坦,J.(1995年)《自然》377卷,532 - 535页;赖因沙伊德,R.K.,诺塔克,H.-P.,布尔森,A.,阿尔达蒂,A.,亨宁森,R.A.,邦佐,J.R.,格兰迪,D.K.,朗根,H.,蒙斯马,F.J.,Jr.,和奇韦利,O.(1995年)《科学》270卷,792 - 794页)。在本研究中,发现豚鼠脑内含有一些受体,痛敏肽与这些受体的结合比与在人类293细胞中表达的ORL1受体的结合要强得多。虽然强啡肽A的Tyr1→Phe取代几乎完全消除了其与阿片受体的结合能力,但发现痛敏肽中的Phe1→Tyr取代在甩尾试验中几乎完全保留了受体结合亲和力和体内痛觉过敏活性。痛敏肽与阿片受体的结合非常弱,而Tyr1 - 痛敏肽由于其N端与阿片肽的序列一致性,其亲和力增加了10 - 40倍,尤其是对μ受体。已知强啡肽A的缩短类似物保留了受体结合能力和镇痛活性,而从痛敏肽中去除C端六肽或十肽则完全消除了对ORL1受体的亲和力。这些结果表明,痛敏肽与ORL1受体之间的相互作用模式与强啡肽和阿片受体之间的相互作用模式有很大不同,并表明痛敏肽的C端部分对受体识别至关重要。